Fig. 4.
Fig. 4. Treatment of HL-60 and NB4 cells by retinoids in the presence of retinoic acid receptor antagonists. (▪) SERCAPLIM; (□) SERCA 2b. (A) Treatment of NB4 cells by 0.1 μmol/L TTNPB (a pan-RAR agonist) in the presence or absence of 10 μmol/L Ro61-8431 (a pan-RAR antagonist). (B) Treatment of NB4 cells with various concentrations of AM580 (an RAR selective agonist). (C) Treatment of HL-60 cells with 0.1 μmol/L ATRA in the presence or absence of 10 μmol/L Ro41-5253 (an RAR specific antagonist). Data represent the mean ± SEM of 3 experiments.

Treatment of HL-60 and NB4 cells by retinoids in the presence of retinoic acid receptor antagonists. (▪) SERCAPLIM; (□) SERCA 2b. (A) Treatment of NB4 cells by 0.1 μmol/L TTNPB (a pan-RAR agonist) in the presence or absence of 10 μmol/L Ro61-8431 (a pan-RAR antagonist). (B) Treatment of NB4 cells with various concentrations of AM580 (an RAR selective agonist). (C) Treatment of HL-60 cells with 0.1 μmol/L ATRA in the presence or absence of 10 μmol/L Ro41-5253 (an RAR specific antagonist). Data represent the mean ± SEM of 3 experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal